Title: |
Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence |
Dateline: |
2020-05-29
DisplayDateline
|
Byline: |
Robert NJ, O'Shaughnessy J, Annavarapu S, Zhou J, Sussell J, Cheng A, Fung A |
Publication Title: |
ASCO
|
CTA Link: |
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e12648 |
CTA Text: |
Read More |
Filter(s):* This
creates the tags that filter the listing page by specific taxonomies that display to the right of the
main content and read more link.
|
-
|